Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HL2351 in Healthy Volunteers
NCT02175056Phase 1Completed
- Sponsor
- Handok
- Start
- May 2014
- Primary completion
- Jan 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hl2351 in rheumatoid arthritis (RA) (3 arms), sponsored by Handok. Primary endpoints: Tolerability as measured by the occurrence of Adverse Events at 29 days, Tolerability as measured by Physical Examination, Vital Signs and Safety Laboratory Tests at 29 days and 10 more. Started May 2014; status: completed.
02
Drugs
hl2351
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02175056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175056.